Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2019
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. The following metrics are disclosed:
- Capital Raised: $2.0 million
- Shares Issued: 1,212,121 shares of Class A common stock
- Price Per Share: $1.65
- Investor: MacAndrews & Forbes Group LLC
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The material change reported is the execution of a purchase obligation under the "March 2019 Letter Agreement." On August 6, 2019, the Company exercised its right to require the Investor to purchase the aforementioned shares, resulting in an immediate increase in cash and outstanding equity.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction is qualified by reference to the March 2019 Letter Agreement (Exhibit 10.2 to the March 20, 2019 Form 8-K).
Investor Verification Checklist
- Verify the terms of the March 2019 Letter Agreement referenced in the filing to understand the full scope of the investment relationship.
- Confirm the dilution impact of the 1,212,121 newly issued shares on existing shareholders.
- Review the Company's most recent 10-Q or 10-K for updated cash position and burn rate following this $2.0 million infusion.
- Check for any subsequent filings regarding the use of proceeds from this capital raise.